Xenon Pharmaceuticals (XENE) Expected to Announce Quarterly Earnings on Thursday

Xenon Pharmaceuticals (NASDAQ:XENE) is expected to be issuing its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($1.20) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $42.51 on Thursday. The stock has a market cap of $3.29 billion, a PE ratio of -10.93 and a beta of 0.96. The firm has a 50-day moving average of $42.48 and a 200-day moving average of $40.58. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $46.60.

Insider Transactions at Xenon Pharmaceuticals

In related news, CEO Ian Mortimer sold 40,000 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the transaction, the chief executive officer owned 6,000 shares of the company’s stock, valued at $266,580. The trade was a 86.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 65,302 shares of company stock valued at $2,924,128. Company insiders own 4.07% of the company’s stock.

Institutional Trading of Xenon Pharmaceuticals

Several hedge funds have recently made changes to their positions in XENE. Mackenzie Financial Corp bought a new stake in Xenon Pharmaceuticals during the 4th quarter valued at $210,000. ADAR1 Capital Management LLC grew its position in shares of Xenon Pharmaceuticals by 7.9% in the fourth quarter. ADAR1 Capital Management LLC now owns 203,969 shares of the biopharmaceutical company’s stock valued at $9,142,000 after purchasing an additional 14,871 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $964,000. Virtus Investment Advisers LLC raised its stake in shares of Xenon Pharmaceuticals by 74.0% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,037 shares of the biopharmaceutical company’s stock valued at $271,000 after purchasing an additional 2,568 shares during the period. Finally, Squadron Capital Management LLC bought a new position in Xenon Pharmaceuticals in the 4th quarter worth about $4,731,000. 95.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

XENE has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $55.00 price objective on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Cantor Fitzgerald reissued an “overweight” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, November 4th. Wells Fargo & Company boosted their target price on shares of Xenon Pharmaceuticals from $44.00 to $48.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Finally, JPMorgan Chase & Co. raised their price objective on Xenon Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Friday, January 9th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $54.73.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.